Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy Basel, 19 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more
Roche v-TAC is a new digital diagnostics solution that allows clinicians to obtain arterial blood gas values from patients in need of blood gas testing via a simpler, less painful and less invasive venous method Roche’s new digital tool could help simplify the screening, diagnosis and monitoring of patients with respiratory compromise in the current... Read more
Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer Full results will be presented in an oral abstract session at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO) Basel, 14 May 2020 – Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 11 Mai 2020 – On May 10th 2020 Dr. h.c. Fritz Gerber died in his 92nd year. For more than two decades, he had shaped Roche’s development into a leading global healthcare company in an exceptionally successful dual role as Group CEO (1978-1998) and Chairman of the Board (1978-2001). He remained closely associated with... Read more
Basel, 11 May 2020 Roche today announced that Michael Varney (1958) Ph.D., and Head of Genentech Research and Early Development (gRED) since 2015, will retire from the company at the end of July. Aviv Regev (1971), Ph.D., and currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the... Read more
First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020,... Read more
The serology test has a specificity greater than 99.8% and sensitivity of 100% (14 Days post-PCR confirmation) The high specificity of the test is crucial to determine reliably if a person has been exposed to the virus and if the patient has developed antibodies Roche will provide high double-digit millions of tests already in May... Read more
Post-hoc analysis from 6 years of Phase III open-label extension studies showed OCREVUS treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) patients compared with patients who switched from interferon beta-1a two years later Separate analysis showed OCREVUS slowed thalamic volume loss in patients with RMS and... Read more
FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatment Large, pivotal global study confirms clinically meaningful efficacy seen in the dose-finding Part 1 of the trial Safety was consistent with the safety profile observed to date and no... Read more
Basel, 22 April 2020 Group sales increase 2% in Swiss francs and 7%1 at constant exchange rates, driven by new products, more than compensating for impact of competition from biosimilars Pharmaceuticals Division sales up 7%, led by Tecentriq, Hemlibra, Ocrevus and Perjeta Diagnostics Division sales grow 5%, with molecular testing as main contributor Important approvals... Read more